In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectral Genomics Inc.

Division of PerkinElmer Inc.
www.spectralgenomics.com

Latest From Spectral Genomics Inc.

Noninvasive Prenatal Diagnostics: How Much Closer to Reality?

Whether the astonishing missteps by Sequenom, which earlier this year disclosed it could not support its data for a non-invasive Down Syndrome test, were merely poor management or a reality check for the field of non-invasive prenatal disgnostics, the NIPD opportunity is compelling. But the profession also understandably balks at obtaining information that is not then clinically actionable -- an issue that could further amplify in importance as technologies like microarrays and direct DNA sequencing increase become more prevalent.
Medical Device Platform Technologies

Women's Health: A Growing Market for Diagnostic Players

Women's health is an area long shunned by pharmaceutical and diagnostic companies. But that is starting to change thanks to the successes of companies such as Cytyc and Digene, who have built successful testing franchises in the Ob/ Gyn market. As companies such as PerkinElmer and others look to develop new tests in this market, a spate of start-ups are developing technologies that might fit the bill. Of greatest interest are the so-called molecular tests since they offer the advantage of premium pricing.
Medical Device Platform Technologies

Molecular Diagnostics--From Tools to Tests

Instrument makers have made big money off the genomics revolution. But as the research market slows, companies are looking for new business opportunities. One area ripe for development: the molecular diagnostics market.
BioPharmaceutical Medical Device

Spectral Genomics Inc.

Spectral Genomics Inc., aims to become one of the first, if not the first, to bring a diagnostic microarray through to FDA approval. Spectral belives its BAC clone arrays offer major advantages in detecting large scale chromosomal amplifications, deletions and rearrangements characteristic of cancers and many congenital defects. The speed and universality of the arrays make them potentially practical for low-cost, high-speed, and targeted diagnostic purposes.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological > Obstetrics
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PerkinElmer Inc.
  • Senior Management
  • Edward M Chait, PhD, CEO
    Tom Martin, CFO
    Mr. Smit, Dir., Bus. Dev.
    Robert Johnson, PhD, Pres. & COO
    Mr. Winkler, VP, Sales & Mktg.
  • Contact Info
  • Spectral Genomics Inc.
    Phone: (713) 797-0092
    8080 North Stadium Dr.
    Houston, TX 77054
    USA
UsernamePublicRestriction

Register